Next Article in Journal
Assessment of In-Situ Gelling Microemulsion Systems upon Temperature and Dilution Condition for Corneal Delivery of Bevacizumab
Next Article in Special Issue
An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery
Previous Article in Journal
Directed Transport of CRP Across In Vitro Models of the Blood-Saliva Barrier Strengthens the Feasibility of Salivary CRP as Biomarker for Neonatal Sepsis
Previous Article in Special Issue
Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 13
Issue 2
10.3390/pharmaceutics13020257
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model

by
Bassel Akache
1,
Gerard Agbayani
1,
Felicity C. Stark
1,
Yimei Jia
1,
Renu Dudani
1,
Blair A. Harrison
1,
Lise Deschatelets
1,
Vandana Chandan
1,
Edmond Lam
2,
Usha D. Hemraz
2,
Sophie Régnier
2,
Lakshmi Krishnan
1 and
Michael J. McCluskie
1,*
1
Human Health Therapeutics, National Research Council Canada, Ottawa, ON K1A 0R6, Canada
2
Aquatic and Crop Resource Development, National Research Council Canada, Montreal, QC H4P 2R2, Canada
*
Author to whom correspondence should be addressed.
Pharmaceutics 2021, 13(2), 257; https://doi.org/10.3390/pharmaceutics13020257
Submission received: 19 January 2021 / Revised: 8 February 2021 / Accepted: 9 February 2021 / Published: 12 February 2021
(This article belongs to the Special Issue Discovery and Evaluation of Novel Adjuvants for Vaccine Formulations)
Browse Figures
Versions Notes

Abstract

Cancer remains a leading cause of morbidity and mortality worldwide. While novel treatments have improved survival outcomes for some patients, new treatment modalities/platforms are needed to combat a wider variety of tumor types. Cancer vaccines harness the power of the immune system to generate targeted tumor-specific immune responses. Liposomes composed of glycolipids derived from archaea (i.e., archaeosomes) have been shown to be potent adjuvants, inducing robust, long-lasting humoral and cell-mediated immune responses to a variety of antigens. Herein, we evaluated the ability of archaeosomes composed of sulfated lactosyl archaeol (SLA), a semi-synthetic archaeal glycolipid, to enhance the immunogenicity of a synthetic long peptide-based vaccine formulation containing the dominant CD8+ T cell epitope, SIINFEKL, from the weakly immunogenic model antigen ovalbumin. One advantage of immunizing with long peptides is the ability to include multiple epitopes, for example, the long peptide antigen was also designed to include the immediately adjacent CD4+ epitope, TEWTSSNVMEER. SLA archaeosomes were tested alone or in combination with the toll-like receptor 3 (TLR3) agonist Poly(I:C). Overall, SLA archaeosomes synergized strongly with Poly(I:C) to induce robust antigen-specific CD8+ T cell responses, which were highly functional in an in vivo cytolytic assay. Furthermore, immunization with this vaccine formulation suppressed tumor growth and extended mouse survival in a mouse melanoma tumor model. Overall, the combination of SLA archaeosomes and Poly(I:C) appears to be a promising adjuvant system when used along with long peptide-based antigens targeting cancer.
Keywords: archaeosome; SLA; vaccine; adjuvant; glycolipid; synthetic long peptide; Poly(I:C); cancer archaeosome; SLA; vaccine; adjuvant; glycolipid; synthetic long peptide; Poly(I:C); cancer
Graphical Abstract

Share and Cite

MDPI and ACS Style

Akache, B.; Agbayani, G.; Stark, F.C.; Jia, Y.; Dudani, R.; Harrison, B.A.; Deschatelets, L.; Chandan, V.; Lam, E.; Hemraz, U.D.; et al. Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model. Pharmaceutics 2021, 13, 257. https://doi.org/10.3390/pharmaceutics13020257

AMA Style

Akache B, Agbayani G, Stark FC, Jia Y, Dudani R, Harrison BA, Deschatelets L, Chandan V, Lam E, Hemraz UD, et al. Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model. Pharmaceutics. 2021; 13(2):257. https://doi.org/10.3390/pharmaceutics13020257

Chicago/Turabian Style

Akache, Bassel, Gerard Agbayani, Felicity C. Stark, Yimei Jia, Renu Dudani, Blair A. Harrison, Lise Deschatelets, Vandana Chandan, Edmond Lam, Usha D. Hemraz, and et al. 2021. "Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model" Pharmaceutics 13, no. 2: 257. https://doi.org/10.3390/pharmaceutics13020257

APA Style

Akache, B., Agbayani, G., Stark, F. C., Jia, Y., Dudani, R., Harrison, B. A., Deschatelets, L., Chandan, V., Lam, E., Hemraz, U. D., Régnier, S., Krishnan, L., & McCluskie, M. J. (2021). Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model. Pharmaceutics, 13(2), 257. https://doi.org/10.3390/pharmaceutics13020257

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop